WZB117 reduces intracellular glucose levels by inhibiting GLUT1 function and has anti-tumor effects on various malignant cells (Liu et al., 2012; Li et al., 2019; Peng et al., 2019; Shima et al., 2022). Here, SLC2A1 is linked to neoplasm.